ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO1002

Combined Assessment of Serum Anti-PLA2Rabs and Glomerular PLA2Rags Deposition in Patients with Membranous Nephropathy (MN)

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Kouki, Pinelopi, Hippokration Hospital of Arhens, Athens, Greece
  • Damianaki, Aikaterini A., Hippokration Hospital of Arhens, Athens, Greece
  • Ventouri, Evgenia, 1st Department Of Pathology School of Medicine University of Athens, Athens, Greece
  • Kapota, Athanasia, Hippokration Hospital of Arhens, Athens, Greece
  • Stylianou, Kostas, University Hospital of Heraklion , Heraklion, Greece
  • Gakiopoulou, Harikleia, 1st Department Of Pathology School of Medicine University of Athens, Athens, Greece
  • Petras, Dimitrios I., Hippokration Hospital of Arhens, Athens, Greece
Background

MN is the most common cause of nephrotic syndrome in adults. The involvement of PLA2R (Ags and Abs) in the pathogenesis of the disease (idiopathic MN) is investigated. The purpose of the study was to correlate the glomerular deposition of PLA2R-antigens (Ags ) and circulating serum anti-PA2R-antibodies (Abs) to renal function (eGFR), proteinuria and clinical outcome in patients with idiopathic MN.

Methods

Twenty patients with idiopathic MN met the study criteria. Initial eGFR and proteinuria were recorded at months 0 and 6 as well as the clinical outcome after treatment. Glomerular PLA2R-Ags deposition intensities (mild, moderate, strong) were evaluated with immunohistochemistry. Serum anti-PLA2R-Abs (detectable / undetectable) were also evaluated.

Results

Positive PLA2R-Ags was detected at 81.25%, while detectable anti-PLA2R-Abs in 62.5% of patients. Mean proteinuria values at months 0 and 6 were 9.1 grams and 1.8 grams / 24 hours, respectively. Μean eGFR at months 0 and 6 was 73.1 ml / min / 1.73 m2 and 75.83 ml / min / 1.73 m2. Strong glomerular PLA2R-Ags deposition was positively correlated with renal function at time 0 (p <0.05) and reduction in proteinuria at 6 months (p <0.01). Serum anti-PLA2R-Abs levels were not correlated with eGFR and proteinuria at 0 and 6 months. Our results are not in accordance with the literature, probably due to early refferal of the patients.

Conclusion

In conclusion glomerular PLA2R-Ags deposition appears to be more closely correlated with renal function and the rate of proteinuria reduction than serum anti-PLA2R-Abs in patients with idiopathic MN. More studies are needed to prove this predictive role.